TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04792671

Intervention type: BEHAVIORAL
Intervention: Sociodemographic variables
Description: age, residence, education of the mother and her husband, occupation of the mother and her husband, parity, gender, and age of the last baby.

Intervention type: BEHAVIORAL
Intervention: Sociodemographic variables
Description: age, residence, education of the mother and her husband, occupation of the mother and her husband, parity, gender, and age of the last baby.

Intervention type: BEHAVIORAL
Intervention: Family affluence scale (FAS)
Description: a four-item measure of family wealth, has been developed in the WHO Health Behaviour in School-aged Children Study as an alternative measure.

Intervention type: BEHAVIORAL
Intervention: Family affluence scale (FAS)
Description: a four-item measure of family wealth, has been developed in the WHO Health Behaviour in School-aged Children Study as an alternative measure.

Intervention type: BEHAVIORAL
Intervention: Edinburgh postnatal depression scale (EPDS)
Description: s a questionnaire originally developed to assist in identifying possible symptoms of depression in the postnatal period. It also has adequate sensitivity and specificity to identify depressive symptoms in the antenatal period and is useful in identifying symptoms of anxiety. more than 9 is clinically diagnosed

Intervention type: BEHAVIORAL
Intervention: Edinburgh postnatal depression scale (EPDS)
Description: s a questionnaire originally developed to assist in identifying possible symptoms of depression in the postnatal period. It also has adequate sensitivity and specificity to identify depressive symptoms in the antenatal period and is useful in identifying symptoms of anxiety. more than 9 is clinically diagnosed

Intervention type: BEHAVIORAL
Intervention: Symptom Checklist 90 SCL 90:
Description: is a 90-item questionnaire used to assess psychological problems. It is designed to evaluate a broad range of psychological problems and symptoms of psychopathology. More than 60 is considered clinically diagnosed

Intervention type: BEHAVIORAL
Intervention: Symptom Checklist 90 SCL 90:
Description: is a 90-item questionnaire used to assess psychological problems. It is designed to evaluate a broad range of psychological problems and symptoms of psychopathology. More than 60 is considered clinically diagnosed
Study: NCT04930042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stelara
Description: AVT04 or Stelara (45 mg/5ml) will be administered as a subcutaneous injection in the thigh or abdomen per the approved dosing regimen for moderate to severe chronic PsO for patients with a body weight ≤100 kg.11,12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVT04
Description: AVT04 or Stelara (45 mg/5ml) will be administered as a subcutaneous injection in the thigh or abdomen per the approved dosing regimen for moderate to severe chronic PsO for patients with a body weight ≤100 kg.11,12
Study: NCT05906186

Intervention type: BEHAVIORAL
Intervention: kiwifruit
Description: eating two kiwifruits a day
Study: NCT03042169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Chemotherapy
Description: Standard chemotherapy regiments according to risk of recurrence

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: the surgical treatment will undergo gastrectomy between D1 and D30 after randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative chemotherapy
Description: Chemotherapy should be restarted between D1 and D30 post-randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Description: Chemotherapy should be restarted between D1 and D30 post-randomization
Study: NCT05997823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesiotape
Description: The button hole technique was used for area correction during the KT application (Figure 1). Two I-tapes were applied, one from the medial epicondyle to the proximal phalanx on the palmar side and the other from the lateral epicondyle to the proximal phalanx on the dorsal side. The area where the phalanges are located was marked, and two hole was drilled in the center.After cleaning the skin with alcohol, the tape to be applied to the palmar side was passed over the 3rd and 4th fingers, and the patient was asked to perform radial deviation and wrist extension

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesiotape
Description: The button hole technique was used for area correction during the KT application (Figure 1). Two I-tapes were applied, one from the medial epicondyle to the proximal phalanx on the palmar side and the other from the lateral epicondyle to the proximal phalanx on the dorsal side. The area where the phalanges are located was marked, and two hole was drilled in the center.After cleaning the skin with alcohol, the tape to be applied to the palmar side was passed over the 3rd and 4th fingers, and the patient was asked to perform radial deviation and wrist extension

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home exercises
Description: home exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home exercises
Description: home exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home exercises
Description: home exercises
Study: NCT05210101

Intervention type: DRUG
Group type: OTHER
Intervention: Sotrovimab
Description: Two intravenous (IV) doses of sotrovimab were administered over the study period, the first 500mg, and the second 2000mg, in light of the reduced antiviral neutralization of sotrovimab against the BA.2 subvariant.
Study: NCT05890690

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urea
Description: Diagnostic test with a single weight-adapted dose of oral urea dissolved in 200 ml water together with 5 g of lemon-lime flavor powder (containing maltodextrin and citric acid).~The investigators will make use of the lemon-lime flavor to soften the bitter taste of urea.~- Dose calculation: 0.5 g urea/kg body weight (rounded to no decimal places), with a minimal dose of 30g and a maximal dose of 45g.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urea
Description: Diagnostic test with a single weight-adapted dose of oral urea dissolved in 200 ml water together with 5 g of lemon-lime flavor powder (containing maltodextrin and citric acid).~The investigators will make use of the lemon-lime flavor to soften the bitter taste of urea.~- Dose calculation: 0.5 g urea/kg body weight (rounded to no decimal places), with a minimal dose of 30g and a maximal dose of 45g.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urea
Description: Diagnostic test with a single weight-adapted dose of oral urea dissolved in 200 ml water together with 5 g of lemon-lime flavor powder (containing maltodextrin and citric acid).~The investigators will make use of the lemon-lime flavor to soften the bitter taste of urea.~- Dose calculation: 0.5 g urea/kg body weight (rounded to no decimal places), with a minimal dose of 30g and a maximal dose of 45g.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Diagnostic test with a single weight-adapted dose of placebo dissolved in 200 ml water together with 5 g of lemon-lime flavor powder (containing maltodextrin and citric acid).~The placebo will contain a mixture of bitter herbal substances to mimic the taste of urea.~- Dose calculation: 22 ml of placebo containing 20 ml Ergytonyl®, 1 ml Carmol®, and 1 ml Bitter Liebe®.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Diagnostic test with a single weight-adapted dose of placebo dissolved in 200 ml water together with 5 g of lemon-lime flavor powder (containing maltodextrin and citric acid).~The placebo will contain a mixture of bitter herbal substances to mimic the taste of urea.~- Dose calculation: 22 ml of placebo containing 20 ml Ergytonyl®, 1 ml Carmol®, and 1 ml Bitter Liebe®.
Study: NCT05368402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ladarixin
Description: The two daily oral doses of ladarixin (400 mg each dose) will be administered at about a 12-hour interval (morning and evening; ideally between 6:30/11:30 and 18:30/23:30). At each administration, 2 capsules will be swallowed with a glass of water, at least 2 hours apart from breakfast or dinner

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered with the same ladarixin schedule.
Study: NCT05222438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loncastuximab tesirine
Description: loncastuximab tesirine for maintenance therapy between day 30 and 60 following autoSCT and will receive a total of 6 months of therapy (8 cycles).
Study: NCT05724628

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Description: Subjects will receive surgery (using 3 port Laparoscopic appendectomy) to remove appendix

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics (IV transitioned to oral)
Description: Subjects will be admitted to the hospital for antibiotic treatment, initially with IV antibiotics and then transitioned to by mouth (PO) antibiotics for the rest of the course.~Drugs used would be anything from: zosyn, ciprofloxacin or ceftriaxone and flagyl, augmentin
Study: NCT05994118

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9% (normal saline)
Description: Subcutaneous normal saline injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnetized Normal Saline
Description: Magnetized Normal Saline
Study: NCT04653753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kneeSOFT500
Description: At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use a knee support device.
Study: NCT04761081

Intervention type: BEHAVIORAL
Intervention: Habitual physical activity assessment
Description: 7 days habitual physical activity via accelerometry (ActiGraph GT3x). Specifically steps per day, light physical activity (minutes per day), and moderate to vigorous physical activity (minutes per day).

Intervention type: BEHAVIORAL
Intervention: Habitual physical activity assessment
Description: 7 days habitual physical activity via accelerometry (ActiGraph GT3x). Specifically steps per day, light physical activity (minutes per day), and moderate to vigorous physical activity (minutes per day).

Intervention type: BEHAVIORAL
Intervention: Habitual physical activity assessment
Description: 7 days habitual physical activity via accelerometry (ActiGraph GT3x). Specifically steps per day, light physical activity (minutes per day), and moderate to vigorous physical activity (minutes per day).

Intervention type: BEHAVIORAL
Intervention: Habitual physical activity assessment
Description: 7 days habitual physical activity via accelerometry (ActiGraph GT3x). Specifically steps per day, light physical activity (minutes per day), and moderate to vigorous physical activity (minutes per day).
Study: NCT05448326

Intervention type: OTHER
Intervention: Questionnaire to assess expectations of a diagnosis
Description: Duration 45 minutes

Intervention type: OTHER
Intervention: Questionnaire to assess understanding of previously reported results and expectations of a diagnosis
Description: Duration 30 minutes

Intervention type: BIOLOGICAL
Intervention: Blood sample +/- skin biopsy
Description: 8 ml of blood biopsy: size 3 to 5 mm
Study: NCT05721846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg (up to 240 mg maximum) as i.v. infusion on day 1 (± 3 days) of each 14-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg as i.v. infusion on day 1 cycle 1 and subsequently every 6 weeks (± 3 days)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT: 15 Gy x 1 on a single site of disease on day 1 cycle 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TGFβ-B-15 peptide
Description: Vaccine (500 μl aqueous solution of 200 μg TGFβ-B-15 peptide mixed to an emulsion with 500μl Montanide ISA-51) as s.c. injection on day 1 of the first 6 cycles and subsequently every 4 weeks (± 3 days)
Study: NCT06174376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE Synthetic Cornea Device
Description: Treatment with GORE Synthetic Cornea Device
Study: NCT04913727

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance imaging before the procedure
Description: CMR image acquisition with previously mentioned analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral edge-to-edge repair.
Description: Included patients will undergo Transcatheter mitral edge-to-edge repair.
Study: NCT06471946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT
Description: Patients were treated by VA Conditioning Regimen Allo-HSCT:~Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg/m2 subcutaneous injection qd d1-7, donor stem cells infused from d9
Study: NCT05961410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag olamine
Description: Patients will receive eltrombopag 75 mg/day from ESHAP D6 until end of stem cell harvest.
Study: NCT05893004

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Headache Screening Questionnaire
Description: The Dutch Headache Screening Questionnaire (HSQ) is the only screening questionnaire based on ICHD-3 which has at least moderate confidence in its criterion validity according to GRADE. The HSQ has already been translated into Portuguese and validated5. The HSQ has only 8 items and requires little time to complete. Due to its good sensitivity, the HSQ screening questionnaire is particularly well suited to exclude migraine.
Study: NCT05666128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD-6277
Description: HD-6277 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD-6277
Description: HD-6277 50mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05801510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Muscular Therapy for knee pain
Description: Psychologically informed physiotherapy which uses biofeedback training to reduce muscle overactivity and improve postural control and also encourages people to change the way they react to pain.
Study: NCT05178641

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ninjamas Pyjama Pants
Description: Disposable, absorbent underwear-like pyjama pant specifically designed to manage nocturnal enuresis in children by absorbing involuntary urine loss overnight and keeping the child's bed and clothing dry.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ninjamas Pyjama Pants
Description: Disposable, absorbent underwear-like pyjama pant specifically designed to manage nocturnal enuresis in children by absorbing involuntary urine loss overnight and keeping the child's bed and clothing dry.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participant's Overnight Current Standard of Care
Description: Any disposable or reusable absorbent diaper or pant product available on the US market that is used to absorb involuntary urine loss for children who are wetting the bed at night.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participant's Overnight Current Standard of Care
Description: Any disposable or reusable absorbent diaper or pant product available on the US market that is used to absorb involuntary urine loss for children who are wetting the bed at night.
Study: NCT06647901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG (Indocyanine Green)
Description: Patients will be receive intravenously administrated at a dose of 2 mg/kg on the day before surgery. The drug was dissolved into 250 mL of normal saline and administered using a light-proof infusion apparatus. The time course of administration was 60 min. NIR imaging will be performed during surgery to help identify small tumor residuals.
Study: NCT06647615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR headset
Description: The VR portion of the study will last for 8 weeks. You will be asked to use your headset on a daily basis for at least 30 minutes, but you are free to use the headset as much as you would like.
Study: NCT05821296

Intervention type: DEVICE
Group type: OTHER
Intervention: Crystal Peel
Description: 3 applications performed by a dermatologist.
Study: NCT06511570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sabirnetug (ACU193)
Description: sabirnetug by intravenous infusion

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sabirnetug + rHuPH20
Description: sabirnetug + rHuPH20 by subcutaneous injection
Study: NCT05420857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overground Visual Biofeeback
Description: Subjects participate in biofeedback training for 3 6-minute bouts in a single session.
Study: NCT04939311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-201
Description: One dose of VB-201 80 mg (1 tablet) will be administered orally once daily for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
Study: NCT05429359

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPET: CardioPulmonary Exercise Test for CSII users
Description: * Baseline~* VO2peak measurement~* Breakfast~* 100% bolus insulin~* CSII users: 100% basal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AEX1: Aerobic Exercise Test 1 for CSII users
Description: * 90min~* 40-45% VO2peak~* Breakfast~* 50% bolus insulin~* CSII users: -2h target 150 mg/dL

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AEX2: Aerobic Exercise Test 2 for CSII users
Description: * 90min~* 40-45% VO2peak~* Breakfast~* 50% bolus insulin~* CSII users: -1h target 150 mg/dL

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPET: CardioPulmonary Exercise Test for MDI users
Description: * Baseline~* VO2peak measurement~* Breakfast~* 100% bolus insulin~* MDI users: 100% basal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AEX1: Aerobic Exercise Test 1 for MDI users
Description: * 90min~* 40-45% VO2peak~* Breakfast~* 50% bolus insulin~* MDI users: 50% basal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AEX2: Aerobic Exercise Test 2 for MDI users
Description: * 90min~* 40-45% VO2peak~* Breakfast~* 50% bolus insulin~* MDI users: 80% basal
Study: NCT05967676

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Turkish adaptation, validity and reliability
Description: This study was conducted as test-retest design and the psychometric properties of PRIA-RS were examined in injured athletes
Study: NCT06386029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Power Down bedtime manipulation
Description: The Power Down is a bedtime manipulation protocol targeting elevated arousal level at bedtime due to a hypothesized effect of sensory over-responsivity (a common experience for autistic children). The Power Down incorporates sensory-based tools (gentle tactile pressure and auditory cues) to support nervous system regulation prior to attempting sleep onset. Participants (caregivers and their child) will be educated in the Power Down protocol and data collection methods for the 2 week intervention trial. Caregivers will lead a nightly gentle massage with guided relaxation script just prior to the child trying to fall asleep. The child will also wear a watch-like activity monitor (ActiGraph GT9x) for the 2 week period throughout the day and night to measure changes in sleep and activity patterns. Caregivers will complete daily diary questions in the morning and evening reporting their child's emotions and sleep timing.
Study: NCT04927039

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5ml of inhaled normal saline
Description: After the initiation of OLV, 5ml of normal saline is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 20 minutes after the completion of drug inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20μg (2ml) of inhaled iloprost (Ventavis®) and 3ml of inhaled normal saline
Description: After the initiation of OLV, mixture of iloprost 2ml and normal saline 3ml is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 20 minutes after the completion of drug inhalation.
Study: NCT06258928

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional examination
Description: Compared to nonoperated limb, after 6 months of early rehabilitation.
Study: NCT04473820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vapocoolant spray
Description: The spray will be applied continuously from 25 cm distance for less than 5 seconds to the cannulation site.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine-Prilocaine cream
Description: A finger tip (0.5 gr) of the cream will be applied in 4 square cm at cannulation site and will be covered with closed dressing for 45 minutes.
Study: NCT04880161

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ampion
Description: Inhaled Ampion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled Placebo
Study: NCT06611098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viscosupplements
Description: intra-articular injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Viscosupplements
Description: intra-articular injection
Study: NCT06673095

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excision
Description: Undergo narrow margin excision
Study: NCT05803902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental drug 9MW1911
Description: Experimental drug administered with IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental drug 9MW1911
Description: Experimental drug administered with IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental drug 9MW1911
Description: Experimental drug administered with IV infusion
Study: NCT06673095

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Excision
Description: Undergo wide margin excision
Study: NCT05691608

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Solid tumor and CT DNA
Description: Biopsy and blood sample
Study: NCT04864158

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TSA-group
Description: Reverse total shoulder arthroplasty followed by standard rehabilitation.